HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $47
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $41 to $47.
HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $41 to $47.